KYZATREX® (testosterone undecanoate) CIII capsules
KYZATREX® (testosterone undecanoate) CIII Capsules EXPANDS DISTRIBUTION THROUGH NEW COLLABORATION WITH GAMEDAY MEN’S HEALTH
03. Dezember 2024 09:00 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Gameday Men’s Health, the leader in men’s health clinics nationwide, today announced it is expanding its testosterone therapy options to include...
Marius_logo_CMYK_no background.png
The Testosterone Project Launches on National Testosterone Awareness Day, November 17
15. November 2024 09:49 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Nov. 15, 2024 (GLOBE NEWSWIRE) -- The Testosterone Project, a new nonprofit founded by leading experts in the fields of testosterone treatment and general metabolic health, launches...
Marius_logo_CMYK_no background.png
New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men
14. November 2024 09:30 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, has released compelling new...
Marius_logo_CMYK_no background.png
KYZATREX® (testosterone undecanoate) CIII Capsules Featured in Research at the Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
16. Oktober 2024 09:00 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce that KYZATREX® (testosterone undecanoate) CIII capsules will be highlighted in three research abstracts...
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Partners with UK-Based Numan to Combat Testosterone Deficiency with KYZATREX® (Testosterone Undecanoate) CIII Capsules
18. September 2024 09:00 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce a new partnership with Numan, a leading UK-based, VC-backed digital health platform, to introduce...
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
30. Juli 2024 09:30 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to...
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel
19. September 2023 09:30 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, is proud to announce the...
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)
10. August 2023 09:30 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the...
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
24. Juli 2023 09:00 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or Testosterone Deficiency, is proud to...
Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
20. Juni 2023 08:30 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...